Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 8, 2011, Pages 1741-1750

  Ross, Julie A ^a,b   Blair, Cindy K ^a,b   Cerhan, James R ^d   Soler, John T ^e   Hirsch, Betsy A ^a   Roesler, Michelle A ^a   Higgins, Rodney R ^c   Nguyen, Phuong L ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c ABBOTT NORTHWESTERN HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

^e MINNESOTA DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; NAPROXEN; PARACETAMOL;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK; TREATMENT DURATION;

ACETAMINOPHEN; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MINNESOTA; RISK FACTORS;

EID: 79961213974     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0411     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER cancer statistics review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011.
3. Linet MS, Devesa SS, Morgan GJ. The leukemias. In: Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press; 2006. p. 841-71.
4. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observationalstudies. Lancet 2007;369:1603-13. (Pubitemid 46710123)
5. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009;100:551-7.
6. Khuder SA, Herial NA, Mutgi AB, Federman DJ. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 2005;127:748-54. (Pubitemid 40775501)
7. Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010;127:1680-91.
8. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008;100:1439-47.
9. Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, et al. Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci 2010;55:1533-9.
10. Kasum CM, Blair CK, Folsom AR, Ross JA. Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Cancer Epidemiol Biomarkers Prev 2003;12:534-7. (Pubitemid 36713648)
11. Weiss JR, Baker JA, Baer MR, Menezes RJ, Nowell S, Moysich KB. Opposing effects of aspirin and acetaminophen use on risk of adult acute leukemia. Leuk Res 2006;30:164-9. (Pubitemid 41773336)
12. Walter RB, Milano F, Brasky TM, White E. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective vitamins and lifestyle (VITAL) study. J Clin Oncol 2011;29:2424-31.
13. Slattery ML, Edwards SL, Caan BJ, Kerber RA, Potter JD. Response rates among control subjects in case-control studies. Ann Epidemiol 1995;5:245-9.
14. Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T. Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. Ann Hematol 2005;84:785-91. (Pubitemid 43008551)
15. Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 2010;184:16-20.
16. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
17. Bhayat F, Das-Gupta E, Smith C, Hubbard R. NSAID use and risk of leukaemia: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009;18:833-6.
18. Pogoda JM, Katz J, McKean-Cowdin R, Nichols PW, Ross RK, Preston-Martin S. Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: results from a Los Angeles County case-control study. Int J Cancer 2005;114:634-8. (Pubitemid 40349623)
19. Traversa G, Menniti-Ippolito F, Da Cas R, Mele A, Pulsoni A, Mandelli F. Drug use and acute leukemia. Pharmacoepidemiol Drug Saf 1998;7:113-23. (Pubitemid 28252985)
20. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998;47 Suppl 2:S78-87. (Pubitemid 28493273)
21. Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci US A 2002;99:13371-3. (Pubitemid 35215385)
22. Sjodahl R. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects. Am J Med 2001;110:66S-9S.
23. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66. (Pubitemid 34196319)
24. Bernard MP, Bancos S, Sime PJ, Phipps RP. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des 2008;14:2051-60.
25. Klampfer L, Cammenga J, Wisniewski HG, Nimer SD. Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. Blood 1999;93:2386-94. (Pubitemid 29153643)
26. Bender RP, Lindsey RH Jr, Burden DA, Osheroff N. N-Acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison. Biochemistry 2004;43:3731-9. (Pubitemid 38391728)
27. Ho AD, Brado B, Haas R, Hunstein W. Etoposide in acute leukemia. Past experience and future perspectives. Cancer 1991;67 Suppl:281-4.
28. Bergman K, Muller L, Teigen SW. Series: current issues in mutagenesis and carcinogenesis, No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view. Mutat Res 1996;349:263-88.
29. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005;26:1585-95. (Pubitemid 41389688)
30. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
31. Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB. Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 2005;16:301-8. (Pubitemid 40897849)
32. Slatore CG, Au DH, Littman AJ, Satia JA, White E. Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiol Biomarkers Prev 2009;18:1203-7.
33. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 2006;30:74-7. (Pubitemid 43083548)
34. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med 2005;2:e353.
35. Cooke R, Laing S, Swerdlow AJ. A case-control study of risk of leukaemia in relation to mobile phone use. Br J Cancer 2010;103:1729-35.
36. Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, Ghadirian P, Baghurst PA, Zatonski WA, et al. Past medical history and pancreatic cancer risk: Results from a multicenter case-control study. Ann Epidemiol 2010;20:92-8.
37. Walker AM, Velema JP, Robins JM. Analysis of case-control data derived in part from proxy respondents. Am J Epidemiol 1988;127:905-14.